^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

NKX2-3 expression

i
Other names: NKX2-3, NK2 Homeobox 3, Homeobox Protein NK-2 Homolog C, Homeobox Protein Nkx-2.3, NKX2.3, NKX4-3, NKX2C, CSX3, NK2 Transcription Factor Related, Locus 3 (Drosophila), NK2 Transcription Factor Related, Locus 3, NK-2 (Drosophila) Homolog C, NKX2-3, NK2.3, NKX23
Entrez ID:
Associations
Trials
2years
Quantitative Analysis of NKX2-3 Expression in Human Colon: An Immunohistochemical Study. (PubMed, J Histochem Cytochem)
Furthermore, in most colorectal carcinoma samples, we observed a significant reduction of NKX2-3 expression. These findings indicate that the NKX2-3 transcription factor is produced by both endothelial and non-endothelial tissue constituents in the colon, and its expression changes during aging and in colorectal malignancies. (J Histochem Cytochem XX: XXX-XXX, XXXX).
Journal
|
CD34 (CD34 molecule) • NKX2-3 (NK2 Homeobox 3)
|
NKX2-3 expression
4years
NKL Homeobox Genes NKX2-3 and NKX2-4 Deregulate Megakaryocytic-Erythroid Cell Differentiation in AML. (PubMed, Int J Mol Sci)
FLI1 encodes a master factor for myelopoiesis, driving megakaryocytic differentiation and suppressing erythroid differentiation, thus representing a basic developmental target of these homeo-oncogenes. Taken together, we have identified aberrantly activated NKL homeobox genes NKX2-3 and NKX2-4 in AML, deregulating genes involved in megakaryocytic and erythroid differentiation processes, and thereby contributing to the formation of specific AML subtypes.
Journal
|
FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • NKX2-3 (NK2 Homeobox 3)
|
NKX2-3 expression
over4years
Development and Validation of an Autophagy-Related Signature for Head and Neck Squamous Cell Carcinoma. (PubMed, Biomed Res Int)
The expression of FADD and NKX2-3 in cell lines and HNSCC tissue samples also showed the same trends. ARGs may be a potential biomarker for HNSCC prognosis, and targeted therapies for FADD and NKX2-3 are possible to be a new strategy of HNSCC treatment.
Journal
|
FADD (Fas associated via death domain) • NKX2-3 (NK2 Homeobox 3)
|
NKX2-3 expression